Titre du document / Document title

Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Editorial response

Auteur(s) / Author(s)

AUBIER M. ; VERSTER R. ; REGAMEY C. ; GESLIN P. ; VERCKEN J.-B. ; YOUNG L. S. (Auteur de la réponse) ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Kozell Institute for Arthritis and Infectious Diseases, San Francisco, California, ETATS-UNIS
Hopital Bichat, Service de Pneumologie, Paris, FRANCE
Lesley Williams Hospital, Carltonville, AFRIQUE DU SUD
Hôpital Cantonal, Service de Médecine, Fribeg, SUISSE
Centre Hospitalier Intecommunal, Créteil, FRANCE
Rhône DPC, Anthony, FRANCE

Résumé / Abstract

The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae. Success of treatment was determined by a combination of clinical assessment and chest radiography. Pneumococcal pneumonia was the confirmed diagnosis for 177 patients (54%). Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin, 89% ; amoxicillin, 84%). Sparfloxacin was well-tolerated and produced fewer gastrointestinal effects than amoxicillin. In conclusion, sparfloxacin is a safe and effective alternative to high-dose amoxicillin for the treatment of suspected pneumococcal community-acquired pneumonia.

Revue / Journal Title

Clinical infectious diseases   ISSN 1058-4838   CODEN CIDIEL 

Source / Source

Congrès
Immunomodulation in the Treatment of Invasive Fungal Infections : Present and Future Directions. Educational Symposium, Morristown, NJ , ETATS-UNIS (05/1996)
1998, vol. 26, n^o 6, pp. 1264-1294 [Document : 11 p.] (37 ref.), pp. 1312-1323 [11 page(s) (article)]

Langue / Language

Anglais

Editeur / Publisher

University of Chicago Press, Chicago, IL, ETATS-UNIS  (1992) (Revue)

Mots-clés anglais / English Keywords

Pneumonia ; Bacteriosis ; Streptococcus pneumoniae ; Chemotherapy ; Antibacterial agent ; Amoxicillin ; High dose ; Sparfloxacin ; Single daily dose ; Antibiotic ; Treatment efficiency ; Human ; Fluoroquinolone derivatives ; Quinolone derivatives ; Infection ; Streptococcaceae ; Micrococcales ; Bacteria ; Respiratory disease ; Lung disease ;

Mots-clés français / French Keywords

Pneumonie ; Bactériose ; Streptococcus pneumoniae ; Chimiothérapie ; Antibactérien ; Amoxicilline ; Dose forte ; Sparfloxacine ; Dose journalière unique ; Antibiotique ; Efficacité traitement ; Homme ; Fluoroquinolone dérivé ; Quinolone dérivé ; Infection ; Streptococcaceae ; Micrococcales ; Bactérie ; Appareil respiratoire pathologie ; Poumon pathologie ;

Mots-clés espagnols / Spanish Keywords

Neumonía ; Bacteriosis ; Streptococcus pneumoniae ; Quimioterapia ; Antibacteriano ; Amoxicilina ; Dosis fuerte ; Esparfloxacino ; Dosis diaria única ; Antibiótico ; Eficacia tratamiento ; Hombre ; Fluoroquinolone derivado ; Quinolone derivado ; Infección ; Streptococcaceae ; Micrococcales ; Bacteria ; Aparato respiratorio patología ; Pulmón patología ;

Localisation / Location

INIST-CNRS, Cote INIST : 18407, 35400007567051.0090